Lobe Sciences Announces Creation of Wholly Owned Subsidiary, Alera Pharma, Inc.
August 15 2024 - 9:15PM
Business Wire
- Alera Pharma, Inc. is a newly formed C-Corp wholly owned by
Lobe Sciences, Ltd.
- Mr. Rick Goulburn is appointed as the Chief Executive Officer
of Alera Pharma, Inc.
- Dr. Frederick D. Sancilio has been appointed as Chairman of the
Alera Pharma, Inc. while Dr. Harry Jacobson, Mr. Wesley Ramjeet,
and Mr. Goulburn are appointed as Members of the Board.
- Lobe Sciences Australia Pty Ltd. will become a subsidiary of
Alera Pharma, Inc. and Mr. Ilan Hayman will become a member of the
executive management team of Alera Pharma.
- Intellectual property rights associated with Lobe’s lead
compound, Psilocin Mucate, will move to Alera Pharma.
- Notice of Allowance received from US PTO for US Patent
Application Serial No. 18/411,576.
Lobe Sciences, Ltd ("Lobe Sciences" or the "Company") (CSE:
LOBE), (OTCQB: LOBEF), a biopharmaceutical company focused on
developing products to treat diseases with unmet medical needs,
today announced that is has formed a wholly owned U.S. subsidiary
named Alera Pharma, Inc. (Alera). Alera will be assigned the
intellectual property rights focused on the Company’s neurological
assets and its new chemical entity Psilocin Mucate.
Mr. Rick Goulburn has been appointed as the Chief Executive
Officer of Alera. Dr. Fred D. Sancilio will be Chairman of its
Board of Directors and be joined on the board by Dr. Harry
Jacobson, Mr. Wesley Ramjeet and Mr. Goulburn. Alera will be the
operating company within the Lobe Sciences group focused on
neurology and will join Altemia, LLC as the second operating
subsidiary of Lobe Sciences. It is expected that the Company’s
Australian subsidiary, Lobe Sciences Australia Pty Ltd., will
become a subsidiary of Alera. Mr. Ilan Hayman will become a member
of the executive management team of Alera.
Dr. Sancilio, Chairman and CEO of Lobe Sciences said, “At
present, Lobe Sciences has a complex corporate structure. By
establishing Alera Pharma, we are simplifying the operations of the
Company into just three entities. Lobe Sciences, Ltd will provide
common services to the two operating subsidiaries - Alera and
Altemia, LLC. The creation of two separate operating companies will
allow each entity to create value within their respective
therapeutic areas; neurology and hematology.”
The Company also announces the receipt from the US PTO of a
Notice of Allowance for its U.S. Patent Application Serial No.
18/411,576.
About Lobe Sciences Ltd.
Lobe Sciences is a biopharmaceutical company focused on
developing medicines to treat diseases with unmet medical needs.
The Company, through collaboration with industry-leading partners,
is engaged in novel research and development focused on treating
chronic cluster headache (an orphan disease), refractive anxiety,
and sickle cell disease. The Company is engaged in Phase 1 and
Phase 2 activities in its drug portfolio, and intends to initiate
the launch of Altemia®, a medical food designed to meet the needs
of sickle cell patients globally.
Cautionary Statement Regarding
"Forward-Looking" Information
This news release includes certain statements and information
that may constitute forward-looking information within the meaning
of applicable Canadian securities laws. All statements in this news
release, other than statements of historical facts, including
statements regarding future estimates, plans, objectives, timing,
assumptions or expectations of future performance, including,
without limitation: the composition of the management team of Alera
and the ownership of Lobe Sciences Australia Pty Ltd., are
forward-looking statements and contain forward-looking information.
Generally, forward-looking statements and information can be
identified by the use of forward-looking terminology such as
“intends” or “anticipates”, or variations of such words and phrases
or statements that certain actions, events or results “may”,
“could”, “should” or “would” or occur.
Forward-looking statements are based on certain material
assumptions and analysis made by the Company and the opinions and
estimates of management as of the date of this press release,
including, among other things, that: the management team of Alera
will be appointed as currently expected and that Lobe Sciences
Australia Pty Ltd. will become a subsidiary of Alera as currently
anticipated. These forward-looking statements are subject to known
and unknown risks, uncertainties and other factors that may cause
the actual results, level of activity, performance or achievements
of the Company to be materially different from those expressed or
implied by such forward-looking statements or forward-looking
information. Important risks that may cause actual results to vary,
include, without limitation, the risk that: the management team of
Alera will be appointed differently as currently expected and that
Lobe Sciences Australia Pty Ltd. will not become a subsidiary of
Alera as currently anticipated.
Although management of the Company has attempted to identify
important factors that could cause actual results to differ
materially from those contained in forward-looking statements or
forward-looking information, there may be other factors that cause
results not to be as anticipated, estimated or intended. There can
be no assurance that such statements will prove to be accurate, as
actual results and future events could differ materially from those
anticipated in such statements. Accordingly, readers should not
place undue reliance on forward-looking statements and
forward-looking information. Readers are cautioned that reliance on
such information may not be appropriate for other purposes. The
Company does not undertake to update any forward-looking statement,
forward-looking information or financial out-look that are
incorporated by reference herein, except in accordance with
applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240815293620/en/
For further information: Dr. Fred D. Sancilio, CEO
Lobe Sciences Ltd. Investor and Media Info@Lobesciences.com
Phone: +1 (949) 505-5623 www.lobesciences.com